McKesson Q4 Surprises to Upside, But High Hurdles Remain

What happened

McKesson reported a stronger-than-expected fiscal Q4 and full-year 2026, citing robust growth across oncology, multispecialty, pharmaceutical distribution, and prescription technology. Management framed this as validation of their strategic pivot toward higher-margin platforms and guided for continued earnings growth in fiscal 2027. However, the master report's deep dive reveals that recent profit growth is heavily aided by acquisitions, one-time gains, and aggressive buybacks, with organic volumes and margin expansion less impressive than headline numbers suggest. Meanwhile, the revived West Virginia opioid suit and $5.7B in existing litigation liabilities remain a persistent overhang, constraining capital flexibility despite strong free cash flow. At ~21x forward EPS, the stock already prices in sustained 13–16% compound growth, leaving limited room for error and a risk/reward tilt that favors trimming positions rather than adding.

Implication

Investors should weigh McKesson's strong execution against elevated expectations and litigation risk. The stock's risk/reward is skewed to the downside near $825, as any disappointment on growth or opioid developments could trigger multiple compression. Favor waiting for a pullback to ~$720 or clearer evidence that oncology profit growth is sustainable without acquisition dependence before adding exposure.

Thesis delta

No material shift. The Q4 results corroborate the master report's base-case scenario of mid-teens EPS compounding driven by oncology and buybacks, but do not change the assessment that upside is limited and risk from opioid litigation and growth quality remains underappreciated. The thesis continues to favor trimming near $880 and looking for a better entry near $720.